Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with
median duration of about 14 days. Almost all neutropenia will suffer from febrile without
prophylactic antibiotics. IDSA recommended fluoroquinolones as prophylaxis in neutropenia
patients of high risks, while in China, major pathogens possess high resistance to
fluoroquinolones. It is not clear whether prophylaxis is of benefit, nor the appropriate
prophylaxis regimen.
The current study will evaluate the three different regimen:
1. No prophylaxic antibiotic
2. Piperacillin as prophylaxis for neutropenia patients. Piperacillin has anti-pseudomonas
activity.
3. Piperacillin/tazobactam as prophylaxis for neutropenia patients. Piperacillin/tazobactam
has highest susceptibility rate among common anti-pseudomonas antibiotics.
Phase:
N/A
Details
Lead Sponsor:
Chinese PLA General Hospital
Treatments:
Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam